HeartBeam Snags New Patent For 12-Lead ECG Smartwatch-Based Monitor To Detect Heart Attacks

• HeartBeam Inc (NASDAQ: BEAT) announced that its patent for a 12-lead electrocardiogram (ECG) smartwatch-based monitor intended to detect heart attacks and complex cardiac arrhythmias was allowed by the United States Patent and Trademark Office (USPTO).

• The company says that currently available wearables cannot provide a 12-lead ECG for heart attack detection, complex arrhythmia monitoring, or other cardiac disorders.

• HeartBeam's latest patent further expands on the company's anytime, anywhere capabilities.

• "The breakthrough inventions protected by this patent enable our proprietary 3D ECG technology to be built into a smartwatch, eliminating the need for a dedicated ECG device while offering a 12-lead ECG capability enabling heart attack and complex arrhythmia detection," said HeartBeam CEO and Founder Branislav Vajdic.

• Recently, HeartBeam shares jumped 75% after its patent for a 12-lead electrocardiogram patch monitor intended to detect acute coronary syndrome and cardiac arrhythmia, which the USPTO issued.

• Price Action: BEAT shares are down 1.40% at $3.65 on the last check Wednesday.

See more from Benzinga

• Interim Results Of NanoVibronix's Uroshield Show Beneficial Effects For Patients

• Sunshine Biopharma Collaborates For Its Lead mRNA-Based Cancer Program

• Elon Musk Asked A Top Tesla Executive To Forfeit Unvested Equity Awards And He Promptly Quit: Report - Te

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.